Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01LES
|
||||
| Former ID |
DNCL003530
|
||||
| Drug Name |
MEGF0444A
|
||||
| Synonyms |
RG7414
|
||||
| Indication | Metastatic colorectal cancer; Non-small cell lung cancer [ICD9: 153, 154; ICD10:C18-C21, C33-C34] | Phase 2 | [522678] | ||
| Company |
Genentech
|
||||
| Target and Pathway | |||||
| Target(s) | EGF-like domain-containing protein 7 | Target Info | Modulator | [549982] | |
| References | |||||
| Ref 549982 | A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.